69,801 Shares in Medtronic PLC $MDT Bought by Caprock Group LLC

Caprock Group LLC bought a new stake in shares of Medtronic PLC (NYSE:MDT) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 69,801 shares of the medical technology company’s stock, valued at approximately $6,478,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MDT. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic in the 2nd quarter valued at about $27,000. Corundum Trust Company INC acquired a new stake in Medtronic during the third quarter worth about $27,000. Valley Wealth Managers Inc. purchased a new position in Medtronic during the third quarter valued at approximately $29,000. Steigerwald Gordon & Koch Inc. acquired a new position in Medtronic in the third quarter valued at approximately $33,000. Finally, Tripletail Wealth Management LLC acquired a new position in Medtronic in the third quarter valued at approximately $34,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. JPMorgan Chase & Co. increased their price target on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. UBS Group reiterated a “neutral” rating and issued a $104.00 price objective on shares of Medtronic in a research report on Wednesday, February 4th. Finally, Needham & Company LLC upgraded Medtronic from a “hold” rating to a “buy” rating and set a $121.00 target price on the stock in a research report on Monday. Sixteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $111.21.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire CathWorks for $585 million — expands its cath-lab/FFR imaging capabilities and strengthens the cardiovascular franchise, a strategic tuck-in that could accelerate revenue and cross‑sell opportunities. Medtronic to Buy CathWorks for $585M
• Positive Sentiment: Needham upgraded MDT to a “buy” and set a $121 price target (~19% upside from current levels) — the upgrade can attract buying interest and supports near-term sentiment. Needham upgrades Medtronic (MDT)
• Positive Sentiment: Analysts and trade press note new product momentum and related rating boosts — fresh product launches/approvals bolster growth narrative and margin leverage over time. Medtronic stock gets a ratings boost on new products
• Positive Sentiment: Outlook drivers: Zacks highlights strength in Medtronic’s cardiovascular unit as a likely lift to Q3 revenue (projected ~7.3% y/y), which could offset softer EPS. Strength in Cardiovascular Unit Likely to Lift MDT’s Q3 Performance
• Neutral Sentiment: MDT is expected to report earnings this week — the print and any revised FY guidance remain the primary short-term catalyst. Medtronic (MDT) Expected to Announce Earnings on Tuesday
• Neutral Sentiment: Analyst/market narratives are shifting as Medtronic’s strategic moves and pipeline progress get priced in — read for context on repositioning and valuation. How Recent Moves Are Quietly Rewriting The Story For Medtronic (MDT)
• Neutral Sentiment: Market note: the stock recently dipped while broader markets gained — a short-term trading signal but not a fundamental verdict. Medtronic (MDT) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: An antitrust verdict awarded roughly $381.7M in damages against Medtronic — this legal cost and any follow‑on litigation/settlement risk can pressure near‑term earnings and valuation multiples. A Look At Medtronic (MDT) Valuation After Major Antitrust Verdict And US$381.7m Damages Award

Medtronic Stock Performance

NYSE:MDT opened at $101.37 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a fifty day moving average of $99.36 and a two-hundred day moving average of $96.28. The stock has a market capitalization of $129.96 billion, a PE ratio of 27.32, a P/E/G ratio of 2.68 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the business earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is presently 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).